OmniAb to Report Second Quarter 2023 Financial Results on August 10
2023年7月31日 - 9:00PM
ビジネスワイヤ(英語)
OmniAb, Inc. (Nasdaq: OABI) will report financial results
for the three and six months ended June 30, 2023 after the close of
the U.S. financial markets on Thursday, August 10, 2023 and will
hold a conference call that same day beginning at 4:30 p.m. Eastern
time.
Conference Call and Webcast Information
What:
OmniAb conference call to discuss
financial results and business updates
Date:
Thursday, August 10, 2023
Time:
4:30 p.m. Eastern time
Conference Call:
U.S. (888) 396-8049
International +1 (416) 764-8646
Conference ID is 10758721
Webcast:
Live and replay webcast of the call with
slides will be available here.
About OmniAb®
OmniAb’s discovery platform provides pharmaceutical industry
partners access to diverse antibody repertoires and high-throughput
screening technologies to enable discovery of next-generation
therapeutics. At the heart of the OmniAb platform is the Biological
Intelligence™ (BI) of our proprietary transgenic animals, including
OmniRat®, OmniChicken® and OmniMouse® that have been genetically
modified to generate antibodies with human sequences to facilitate
development of human therapeutic candidates. OmniFlic® (transgenic
rat) and OmniClic® (transgenic chicken) address industry needs for
bispecific antibody applications though a common light chain
approach, and OmniTaur™ features unique structural attributes of
cow antibodies for complex targets. We believe the OmniAb animals
comprise the most diverse host systems available in the industry
and they are optimally leveraged through computational antigen
design and immunization methods, paired with high-throughput single
B cell phenotypic screening and mining of next-generation
sequencing datasets with custom algorithms to identify fully human
antibodies with superior performance and developability
characteristics. These proprietary technologies are joined with and
leverage OmniDeep, which is a suite of in silico tools for
therapeutic discovery and optimization that are woven throughout
OmniAb’s various technologies and capabilities. Additionally, an
established core competency focused on ion channels and
transporters further differentiates OmniAb’s technology and creates
opportunities in many emerging target classes. OmniAb antibodies
have been leveraged across modalities, including bispecific
antibodies, antibody-drug conjugates and others.
The OmniAb suite of technologies span from BI-powered repertoire
generation to cutting edge antibody discovery and optimization
offering a highly efficient and customizable end-to-end solution
for the growing discovery needs of the global pharmaceutical
industry.
For more information, please visit www.omniab.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230731599168/en/
OmniAb, Inc. Neha Singh, Ph.D. investors@OmniAb.com Twitter
@OmniAbTech (510) 768-7760
OmniAb (NASDAQ:OABI)
過去 株価チャート
から 5 2024 まで 6 2024
OmniAb (NASDAQ:OABI)
過去 株価チャート
から 6 2023 まで 6 2024